Lung cancer
Conditions
Interventions
Test group:Ultrasound-guided transbronchial mediastinal lymph node frozen biopsy combined with pathological rapid on-site assessment
Control group:Surgical removal of mediastinal lymph nodes using mediastinoscopy or thoracoscopy
Sponsors
Shanghai Pulmonary Hospital, Tongji University School of Medicine
Eligibility
Sex/Gender
All
Age
16 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Chest enhanced CT suggests the presence of lung shadows and mediastinal lymph node enlargement. Imaging suggests the possibility of lung cancer, but no definitive diagnosis has been made. Clinically, it is considered a newly diagnosed patient with the possibility of lung cancer; 2. The patient is unable to obtain tissue for pathological diagnosis through routine bronchoscopy brushing or biopsy, and no cancer cells were found in sputum examination; 3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-3 points; 4. Electrocardiogram, heart function, lung function, blood routine, and coagulation indicators are all normal; 5. No other organic diseases that affect the operation; 6. Can tolerate general anesthesia.
Exclusion criteria
Exclusion criteria: 1. Clear diagnosis of lung cancer patients; 2. Patients who have received airway therapy; 3. Patients with airway obstruction who cannot undergo bronchoscopy examination; 4. Expected survival period<1 month; 5. The shortest diameter of mediastinal lymph nodes is less than 1cm; 6. Mediastinal lymph nodes are located in areas that cannot be sampled by EBUS; 7. Abnormal blood coagulation or other hemorrhagic diseases; 8. Existence of active infectious diseases; 9. Having serious heart function or other organic diseases; 10. Patients with systemic infections; 11. There are contraindications to anesthesia; 12. Breastfeeding or pregnant women; 13. There are uncontrollable mental illnesses; 14. Patients who have participated or are currently participating in clinical trials of other drugs or devices before enrollment; 15. Other situations assessed by researchers as unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological analysis;Genetic testing;Molecular detection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Economic cost; | — |
Countries
China
Contacts
Public ContactJun Zhu
Shanghai Pulmonary Hospital, Tongji University School of Medicine
Outcome results
None listed